Canada markets closed

Sterling Capital Virginia Intermediate Tax-Free Fund Institutional Shares (BVATX)

Nasdaq - Nasdaq Delayed Price. Currency in USD
Add to watchlist
12.090.00 (0.00%)
At close: 8:01PM EDT
Full screen
Previous Close12.09
YTD Return-0.63%
Expense Ratio (net)0.56%
CategoryMuni Single State Interm
Last Cap Gain0.00
Morningstar Rating★★★★★
Morningstar Risk RatingAverage
Sustainability RatingN/A
Net Assets82.82M
Beta (5Y Monthly)0.75
Yield1.67%
5y Average ReturnN/A
Holdings Turnover15.44%
Last Dividend0.02
Average for CategoryN/A
Inception DateMay 17, 1999
  • Philips Earns Ultimate Score of 100 on Human Rights Campaign Foundation’s Annual Assessment of LGBTQ Workplace Equality
    Business Wire

    Philips Earns Ultimate Score of 100 on Human Rights Campaign Foundation’s Annual Assessment of LGBTQ Workplace Equality

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it received a score of 100 on the Human Rights Campaign Foundation’s 2021 Corporate Equality Index (CEI), the nation’s foremost benchmarking survey and report measuring corporate policies and practices related to LGBTQ workplace equality. This is the third consecutive year in which Philips has been named to this prestigious list – and the first time scoring 100% – recognizing the company’s relentless focus on diversity, equity and inclusion.

  • Philips integrates 3D ultrasound with innovative software for breakthrough in surveillance of abdominal aortic aneurysms
    GlobeNewswire

    Philips integrates 3D ultrasound with innovative software for breakthrough in surveillance of abdominal aortic aneurysms

    Philips AAA model in progress Philips AAA model results Philips AAA model Jan. 27, 2021 Philips Abdominal Aortic Aneurysm (AAA) Model helps increase diagnostic confidence and improved patient experience compared to current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has introduced the Philips Abdominal Aortic Aneurysm (AAA) Model, providing physicians a more patient-friendly solution compared to the current standard of care for managing AAA patients. Based on 3D ultrasound, Philips AAA Model delivers clinicians accurate diagnostic information without exposing patients to high doses of radiation and nephrotoxic contrast agents. An abdominal aortic aneurysm (AAA) is an aneurysm that forms in the lower part of the aorta. Typically, AAAs are identified incidentally during abdominal imaging exams but, in some cases, remain undetected until rupture. A ruptured AAA has an 80% mortality rate [1], emphasizing the importance of routine surveillance. Philips AAA Model integrates innovative software and leading Philips 3D ultrasound technologies into a single solution to help increase diagnostic confidence and an improved patient experience. The software automatically segments and quantifies the size of the aneurysm sac for surveillance of known native (untreated), and post-EVAR (treated) AAAs. The current standard of care for AAAs includes 2D ultrasound and computed tomography angiography (CTA). Each of these modalities has its drawbacks, including inter-operator variability with 2D ultrasound and patient exposure to high levels of radiation and nephrotoxic contrast agents with CTA. A recent clinical study showed that 3D ultrasound examination for native AAA surveillance has excellent inter-operator reproducibility, superior to that of 2D ultrasound, supporting the broader use of 3D ultrasound in standard AAA surveillance programs [2]. 3D ultrasound has been shown to estimate the diameter and volume of an AAA with acceptable reproducibility and an improved agreement (over 2D ultrasound) with CT [3]. Furthermore, 3D ultrasound has also been proven to correlate significantly better to 3D CT than 2D ultrasound for assessing the maximum diameter of the residual sac post-EVAR, with clinically acceptable reproducibility [4]. “Regular surveillance of abdominal aortic aneurysm patients is essential, but today’s standard of care has downsides,” said Bich Le, Senior Vice President, General Manager Ultrasound at Philips. “Philips Abdominal Aortic Aneurysm (AAA) Model seamlessly integrates leading Philips technologies including Philips Premium Ultrasound System (EPIQ Elite), Philips Array Transducer (X6-1 xMATRIX) and innovative software into a single solution, to help improve the experience and outcomes for clinicians and patients alike.” Launch of Philips Abdominal Aortic Aneurysm (AAA) Model at LINC 2021Philips will debut the AAA Model at the LINC (Leipzig Interventional Course) Summit, Europe’s premiere interventional course for vascular specialists, taking place virtually, Jan. 25-29, 2021. Visit Philips at LINC for more information on Philips AAA model, including live demos, and follow @PhilipsLiveFrom for updates throughout the virtual event. LINC attendees are also invited to attend a Symposium on Aortic Aneurysms, Friday, Jan. 29 at 12:30 PM CET, where clinicians will discuss the highest quality of care in complex EVAR procedure with advanced imaging techniques, from planning to follow-up. Participating in the Symposium is Prof. Henrik Sillesen who will address improving AAA measurement accuracy using innovative Ultrasound 3D volume moderation and xMATRIX. The Philips Abdominal Aortic Aneurysm (AAA) Model is CE marked for sale in Europe and is FDA cleared for sale in the U.S. [1] Age-specific incidence, risk factors, and outcome of acute abdominal aortic aneurysms in a definedpopulation. Howard DP, Banerjee A, Fairhead JF, et al. Br J Surg. 2015;102(8):907–915. doi:10.1002/bjs.9838[2] Clinical validation of three-dimensional ultrasound for abdominal aortic aneurysm. Ghulam, Qasam M. et al.,Journal of Vascular Surgery, Volume 71, Issue 1 [3] Three-dimensional ultrasound evaluation of small asymptomatic abdominal aortic aneurysms. Bredahl, K. etal. European Journal of Vascular and Endovascular Surgery, Volume 49, Issue 3, 289 – 296[4] Three-dimensional ultrasound improves the accuracy of diameter measurement of the residual sac in EVARpatients. K. Bredahl, M. Taudorf, A. Long, L. Lönn, L. Rouet, R. Ardon, H. Sillesen, J.P. Eiberg. European Journalof Vascular and Endovascular Surgery, Volume 46, Issue 5, 2013 For further information, please contact: Kathy O’ReillyPhilips Global Press OfficeTel.: +1 978-221-8919E-mail: kathy.oreilly@philips.com Twitter: @kathyoreilly About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachments Philips AAA model in progress Philips AAA model results Philips AAA model

  • Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon
    GlobeNewswire

    Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon

    Philips Stellarex low-dose drug-coated balloon January 25, 2021 Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the final, five-year results of two major randomized controlled trials (RCTs) that show no difference in all-cause mortality between patients treated with the Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care. Moreover, the studies showed no difference in mortality between the Stellarex DCB and PTA at every 12-month endpoint over the course of the study. Results from the two RCTs were presented at the virtual 2021 Leipzig Interventional Course (LINC). The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT together comprised approximately 600 patients in Europe and the U.S. After five years, the ILLUMENATE EU RCT showed 19.3% mortality among patients treated with the Stellarex DCB compared to 19.4% mortality for those treated with PTA. The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA (20.2%). Both studies had a high vital status follow-up compliance, with the status of over 90% of patients known. “The five-year final results show favourable overall safety of the Stellarex low-dose paclitaxel DCB, and are applicable within an extensive patient cohort,” said Marianne Brodmann, MD, Professor, vascular specialist at the Medical University of Graz, Austria, primary investigator for both trials and a paid consultant to Philips. “Every year, the Stellarex program has demonstrated low mortality rates with no difference in rates between the two patient cohorts.” “These study results build on the robust, consistent long-term data of the Stellarex program and confirm the safety and performance of our unique DCB,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “The Stellarex DCB, with its low drug dose and unique drug coating composition, continues to be an important treatment choice for healthcare providers treating patients with peripheral arterial disease.” Featuring Philips EnduraCoat technology, a unique coating consisting of a polyethylene glycol excipient with amorphous and crystalline paclitaxel particles dispersed in it, Stellarex .035” DCB is unlike any other drug-coated balloon for the treatment of peripheral artery disease. EnduraCoat technology provides efficient drug transfer and effective drug residency coupled with high coating durability and minimal particulate loss, thereby enabling a low therapeutic drug dose. Philips’ Image Guided Therapy business provides complete procedural solutions of systems, smart devices, disease-specific software and services for minimally invasive procedures, helping caregivers decide, guide, treat and confirm the right therapy for each patient during their procedure. For further information, please contact: Mark GrovesPhilips Global Press OfficeTel.: +31 631 639 916E-mail: mark.groves@philips.com Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622 698 001E-mail : fabienne.van.der.feer@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter. Attachment Philips Stellarex low-dose drug-coated balloon